FY2028 EPS Estimates for Chimerix, Inc. Decreased by Capital One Financial (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Research analysts at Capital One Financial cut their FY2028 EPS estimates for Chimerix in a research note issued on Tuesday, August 13th. Capital One Financial analyst N. Quibria now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous forecast of $0.07. The consensus estimate for Chimerix’s current full-year earnings is ($0.85) per share.

A number of other equities analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Chimerix in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Tuesday. Finally, StockNews.com downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday.

Chimerix Stock Performance

Shares of CMRX opened at $1.02 on Thursday. The stock has a fifty day moving average of $0.88 and a 200-day moving average of $0.97. Chimerix has a 52 week low of $0.75 and a 52 week high of $1.30. The stock has a market capitalization of $91.42 million, a price-to-earnings ratio of -1.10 and a beta of 1.20.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same period in the previous year, the firm posted ($0.21) EPS.

Hedge Funds Weigh In On Chimerix

A number of institutional investors have recently modified their holdings of the company. Koshinski Asset Management Inc. bought a new stake in Chimerix during the 1st quarter worth approximately $42,000. Vance Wealth Inc. bought a new position in shares of Chimerix during the fourth quarter valued at about $46,000. Marquette Asset Management LLC boosted its holdings in Chimerix by 24.3% during the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 22,709 shares during the last quarter. Marshall Wace LLP bought a new stake in Chimerix in the 2nd quarter worth about $137,000. Finally, Pale Fire Capital SE increased its position in shares of Chimerix by 113.6% during the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 112,318 shares during the last quarter. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.